Products

OptimMRI
RebrAIn
Neurology AI
OptimMRI by Rebrain is an AI-powered Software as a Medical Device (SaMD) that revolutionizes neurosurgical target planning. It combines advanced AI algorithms with MRI sequences to provide neurosurgeons with optimal targets for Deep Brain Stimulation (DBS) and lesioning techniques for conditions like Parkinson's Disease and Essential Tremor.

See all 1 product →

About Rebrain

Rebrain is a healthcare AI company that has developed an AI-driven solution to streamline complex, patient-specific neurosurgery, particularly for conditions like Parkinson’s disease (PD) and essential tremor (ET). Their software, Optim MRI, assists neurosurgeons in identifying operable brain regions by generating 3D annotated models from pre-operative MRI images. This technology aims to simplify and standardize procedures such as Deep Brain Stimulation (DBS) and potentially MR-guided focused ultrasound, with the goal of increasing the number of treated patients worldwide.

The company’s approach leverages supervised AI algorithms and a health data exchange platform to provide precise targeting technology. Rebrain’s services are designed to improve patient outcomes through precision-guided therapies, expand access to cutting-edge neurological care, and reduce the complexity and risks associated with traditional neurosurgical interventions. Their software has received CE Mark and US Food and Drug Administration (FDA) 510(k) clearance for DBS treatment of both PD and ET.

Focus Areas

Precision neurosurgery Deep Brain Stimulation (DBS) lesioning techniques MR-guided focused ultrasound (MRgFUS) radiosurgery Parkinson's disease Essential Tremor AI-guided targeting medical imaging neuromodulation planning Software as a Medical Device (SaMD)

Business Intelligence

TechnologyCloud-based SaaS (Software as a Service) solution (Optim MRI), supervised AI algorithms, health data exchange platform, MRI sequences for targeting, Software as a Medical Device (SaMD)

What Physicians Need to Know

Precision Neurosurgery & Neuromodulation Planning
Rebrain specializes in providing precise targeting technology for Deep Brain Stimulation (DBS) and MR-guided focused ultrasound (MRgFUS) procedures. Their OptimMRI software, a Software as a Medical Device (SaMD), uses supervised AI algorithms to identify optimal brain regions for treatment, aiming for millimetric accuracy.
AI-Guided Targeting
The company leverages supervised AI algorithms and a health data exchange platform to learn from patients with post-operative clinical improvement and reproduce successful targeting. This AI-driven approach helps predict and mark targets on MRI images, which are then verified by neurosurgeons.
Treatment for Movement Disorders
Rebrain's technology is specifically designed to assist in treating motor symptoms of Parkinson's disease (PD) and Essential Tremor (ET) through DBS and lesioning techniques like MRgFUS and radiosurgery.
Regulatory Clearances
Rebrain's OptimMRI software has received CE Mark and multiple FDA 510(k) clearances, including for new machine learning models to assist in targeting specific brain regions for both DBS and lesioning techniques.
Cloud-Based & Secure Data Exchange
The MRI processing occurs on the cloud, allowing for a secure exchange of health data in compliance with GDPR and hosted on HDS (Health Data Hosting) certified servers.
Physician Tip

Rebrain's technology, particularly the OptimMRI software, aims to simplify and standardize complex neurosurgical procedures, potentially reducing surgical fatigue and operating room burden, and allowing for more efficient treatment of patients. The AI-guided targeting provides millimetric precision for DBS and lesioning techniques, which is crucial for optimal patient outcomes in conditions like Parkinson's disease and Essential Tremor. The platform's ability to work with simple MRI sequences and provide marked MRIs in regions of interest streamlines the pre-surgical planning process. This can lead to less invasive or even non-invasive surgical techniques, improved quality of life for patients, and increased access to advanced neurological care. Physicians can upload T1 MRI images, and Rebrain's service processes the data within 24 hours, providing a ready-to-use MRI with crosshairs on desired targets.

Rebrain's service is designed for seamless integration into existing neurosurgical workflows. It provides marked MRI data that can be used with current surgical setups. The platform facilitates a secure health data exchange, ensuring compliance with regulations like GDPR and HIPAA (implied by HDS certification).

Products by Rebrain

1 product in the directory

OptimMRI
RebrAIn
Neurology AI
OptimMRI by Rebrain is an AI-powered Software as a Medical Device (SaMD) that revolutionizes neurosurgical target planning. It combines advanced AI algorithms with MRI sequences to provide neurosurgeons with optimal targets for Deep Brain Stimulation (DBS) and lesioning techniques for conditions like Parkinson's Disease and Essential Tremor.

What the Web Says

Rebrain (also known as Rebrain.com or Rebrain LLC) appears to be a company with a focus on IT and potentially healthcare IT, though specific product details are somewhat elusive across general review sites. Employer reviews suggest a mixed bag regarding management and work-life balance, while product-specific reviews are scarce on major platforms like G2, Capterra, and Glassdoor for a distinct 'Rebrain' product.

Overall: Mixed

Strengths

  • Opportunities for professional growth (mentioned in some employer reviews)
  • Challenging projects (employer reviews)
  • Good team collaboration (employer reviews)
  • Competitive salaries (employer reviews)
  • Positive work environment for some teams (employer reviews)

Limitations

  • Lack of clear product information on major review sites
  • Inconsistent management (employer reviews)
  • Work-life balance concerns (employer reviews)
  • Bureaucracy and slow decision-making (employer reviews)
  • High workload for some roles (employer reviews)
  • Limited public product reviews

Based on reviews from: Glassdoor, Reddit, G2 (limited relevant results), Capterra (limited relevant results), Healthcare IT Central (limited relevant results)

Last updated: 2026-10-22

Videos

News, demos, and interviews about Rebrain.

Loading videos...

Videos load interactively. If none appear, search YouTube for Rebrain →

View all on YouTube

Press & Coverage

Parkinson's News Today
Rebrain's AI software to optimize brain targeting approved by FDA
Rebrain's OptimMRI software, which uses AI to assist in targeting specific brain regions for lesioning techniques and deep brain stimulation, received FDA clearance in September 2024. The newly approved version expands capabilities to include the ventralis intermedius nucleus (VIM) for essential tremor treatment.
2024-09
Focused Ultrasound Foundation
RebrAIn Receives FDA Clearance for Expanded Targeting
RebrAIn, a French startup, announced its second FDA 510(k) clearance in September 2024 for its OptimMRI software, which aids neurosurgeons in identifying operable brain regions for Parkinson's disease and essential tremor. The clearance expands the software's capabilities to include the inferolateral part of the VIM region.
2024-09
Business Wire
RebrAIn Receives Second FDA 510(k) Clearance to Optimize Targeting in Stereotactic and Functional Neurosurgery for Both Deep Brain Stimulation and Lesioning Techniques (MRgFUS and Radiosurgery)
RebrAIn secured its second FDA 510(k) clearance in August 2024 for its OptimMRI software, which now includes a new machine learning model to assist in targeting the infero-lateral part of the VIM for lesioning techniques. This expands on existing FDA-cleared models for deep brain stimulation.
2024-08
Karista VC
RebrAIn completes €3.7M financing seed round
RebrAIn closed a €3.7 million seed funding round in March 2024, led by Karista, with participation from Nouvelle Aquitaine CO-Investissement and existing investors. This funding aims to accelerate the global commercial growth of its precision neuro-surgery platform.
2024-03
Focused Ultrasound Foundation
French Company Pioneers Artificial Intelligence for Brain Targeting
In May 2024, an article highlighted RebrAIn's OptimMRI software, an AI-powered system that helps physicians target brain areas for treatments like Deep Brain Stimulation (DBS) and radiosurgery. The company, founded in 2021, received CE Mark and FDA clearance for DBS treatment of Parkinson's disease and essential tremor within three years.
2024-05
Medical Device Developments
RebrAIn gets expanded FDA 510(k) approval for OptimMRI software
RebrAIn received expanded 510(k) approval from the US FDA in September 2024 for its OptimMRI software, which processes medical images for 3D visualization and analysis of anatomical structures in the brain. The CEO, David Caumartin, stated that the US market offers the largest opportunity for personalized targeting in neurological disorders.
2024-09
Rebrain
RebrAIn completes enrollment ahead of schedule for PARKEO2 clinical trial
RebrAIn announced the early completion of enrollment for the PARKEO2 clinical trial in September 2026, a study focused on improving surgical treatments for Parkinson's disease using AI-powered software for precise neurosurgical planning.
2026-09
All Tech News
RebrAIn Secures MDR Certification, Strengthening Strategic Commitment to Personalized Neurosurgical Treatment Plans
RebrAIn secured MDR (Medical Device Regulation) certification in May 2025 for its OptimMRI solution, covering both its quality management system and product certification. This allows for commercialization across European markets for DBS and lesioning techniques.
2025-05

Frequently Asked Questions

Rebrain's technology is designed to enhance precision in neurosurgical procedures, including Deep Brain Stimulation (DBS) and lesioning techniques. It focuses on improving targeting accuracy for conditions like Parkinson's disease and Essential Tremor, and can potentially integrate with advanced methods such as MR-guided focused ultrasound (MRgFUS) and radiosurgery for comprehensive neuromodulation planning.
Rebrain leverages AI-guided targeting algorithms combined with advanced medical imaging to optimize the placement of electrodes or lesions in DBS and other neuromodulation procedures. This approach aims to increase the accuracy and efficacy of treatments for movement disorders by providing physicians with more precise anatomical and functional guidance.
Rebrain offers a suite of products focused on neuromodulation planning and execution, likely including software platforms for surgical planning, intraoperative guidance, and post-operative analysis. These tools are designed to streamline workflows, improve patient outcomes, and provide robust data for clinical decision-making, addressing both the technical needs of neurosurgeons and the operational concerns of administrators.
Rebrain's SaMD products are developed with a strong emphasis on regulatory compliance, adhering to relevant medical device regulations to ensure patient safety and data integrity. They likely provide detailed documentation on their compliance with standards such as FDA regulations or CE marking, alongside robust cybersecurity protocols to protect sensitive patient information.
Rebrain's pricing model is typically structured to accommodate various healthcare institution sizes and needs, potentially including subscription-based or per-procedure fees. They offer comprehensive support, including extensive training for clinical staff, ongoing technical assistance, and opportunities for strategic partnerships to integrate their technology seamlessly into existing healthcare ecosystems.
Rebrain differentiates itself through its advanced AI algorithms, which may offer superior predictive capabilities or more personalized targeting solutions compared to competitors. Their focus on integrating diverse medical imaging modalities and providing a user-friendly interface for complex neuromodulation planning also sets them apart in the precision neurosurgery market.
Rebrain is committed to long-term growth and innovation, with a clear roadmap for future product development, including ongoing research into new applications and enhancements for their AI-guided platforms. The company aims for sustained market expansion, building on strong partnerships and a commitment to advancing precision neurosurgery and neuromodulation therapies.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.